Search research articles
Contact Us
Filters
Showing results (171-180 of 193) with videos related to
Page
of 20
Sort By:
Journal for Immunotherapy of Cancer
|
February 10, 2025
Sex and outcomes of patients with microsatellite instability-high and <i>BRAF</i> V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
Vincenzo Nasca, Joseph Zhao, Javier Ros, et al.
Journal of Cancer Policy
|
November 26, 2023
A tailored approach to horizon scanning for cancer medicines
Jennifer A Soon, Yat Hang To, Marliese Alexander, et al.
Lancet (London, England)
|
April 12, 2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H J Simkens, Harm van Tinteren, Anne May, et al.
Cancers
|
August 26, 2023
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
Fang-Shu Ou, Daniel H Ahn, Jesse G Dixon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2024
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
Romain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
Nature Communications
|
October 7, 2018
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Dominiek Smeets, Ian S Miller, Darran P O'Connor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2018
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab
Erik van Dijk, Hedde D Biesma, Martijn Cordes, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 25, 2018
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
Kaitlyn K H Goey, Halfdan Sørbye, Bengt Glimelius, et al.
BMJ Open
|
June 15, 2023
Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial
Maaike E Verweij, Max D Tanaka, Chavelli M Kensen, et al.
Journal of the National Cancer Institute
|
December 22, 2017
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
Katrin M Sjoquist, Lindsay A Renfro, R John Simes, et al.
Page
of 20
Search research articles
Search
Showing results (171-180 of 193) with videos related to
Sort By:
Page
of 20
Journal for Immunotherapy of Cancer
|
February 10, 2025
Sex and outcomes of patients with microsatellite instability-high and <i>BRAF</i> V600E mutated metastatic colorectal cancer receiving immune checkpoint inhibitors
Vincenzo Nasca, Joseph Zhao, Javier Ros, et al.
Journal of Cancer Policy
|
November 26, 2023
A tailored approach to horizon scanning for cancer medicines
Jennifer A Soon, Yat Hang To, Marliese Alexander, et al.
Lancet (London, England)
|
April 12, 2015
Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Lieke H J Simkens, Harm van Tinteren, Anne May, et al.
Cancers
|
August 26, 2023
Evaluation of Intratumoral Response Heterogeneity in Metastatic Colorectal Cancer and Its Impact on Patient Overall Survival: Findings from 10,551 Patients in the ARCAD Database
Fang-Shu Ou, Daniel H Ahn, Jesse G Dixon, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 19, 2024
Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis
Romain Cohen, Morteza Raeisi, Benoist Chibaudel, et al.
Nature Communications
|
October 7, 2018
Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapy
Dominiek Smeets, Ian S Miller, Darran P O'Connor, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2018
Loss of Chromosome 18q11.2-q12.1 Is Predictive for Survival in Patients With Metastatic Colorectal Cancer Treated With Bevacizumab
Erik van Dijk, Hedde D Biesma, Martijn Cordes, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 25, 2018
Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group
Kaitlyn K H Goey, Halfdan Sørbye, Bengt Glimelius, et al.
BMJ Open
|
June 15, 2023
Towards Response ADAptive Radiotherapy for organ preservation for intermediate-risk rectal cancer (preRADAR): protocol of a phase I dose-escalation trial
Maaike E Verweij, Max D Tanaka, Chavelli M Kensen, et al.
Journal of the National Cancer Institute
|
December 22, 2017
Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project
Katrin M Sjoquist, Lindsay A Renfro, R John Simes, et al.
Page
of 20